Soligenix, Inc. - Common Stock (SNGX)
2.2100
+0.00 (0.00%)
NASDAQ · Last Trade: Apr 2nd, 7:28 PM EDT

Soligenix Targets Psoriasis With New Therapy
Via News Direct · January 17, 2025

Soligenix's IIS study on HyBryte for cutaneous T-cell lymphoma shows 70% success and strong safety profile, with Phase 3 enrollment ongoing.
Via Benzinga · January 14, 2025

Soligenix Reports It Is On Cusp Of Treating Rare Cancer CTCL
Via News Direct · December 17, 2024

Soligenix opens enrollment for the Phase 3 FLASH2 study of HyBryte in early-stage CTCL, aiming to confirm extended treatment efficacy over 18 weeks.
Via Benzinga · December 16, 2024

Soligenix, A Pharmaceutical Firm Tackling Potentially Lucrative Unmet Medical Needs
Via News Direct · November 27, 2024

SNGX stock is elevating higher after Soligenix released positive results from its HyBryte study. Here are the company's top investors.
Via InvestorPlace · July 9, 2024

Soligenix starts Phase 2 trial of SGX945 for Behçet's Disease, aiming to enroll 25 patients and report results by mid-2025. Trial includes efficacy assessments.
Via Benzinga · November 14, 2024

Via Benzinga · November 1, 2024

Via Benzinga · October 7, 2024

Via Benzinga · October 3, 2024

Via Benzinga · October 3, 2024

Via Benzinga · October 3, 2024

Via Benzinga · October 2, 2024

There are more than 2,100 stocks under $10 from which to choose in the market. If you want to find the best, use the Portfolio Grader.
Via InvestorPlace · July 31, 2024

Via Benzinga · July 10, 2024

Pre-market stock movers are worth checking out on Wednesday as we break down all of the biggest news worth reading this morning!
Via InvestorPlace · July 10, 2024

Via Benzinga · July 10, 2024

The S&P 500 Index and Nasdaq Composite Index are once again extending their record highs, both modestly higher midday.
Via Talk Markets · July 9, 2024

Via Benzinga · July 9, 2024

Soligenix shares surged on heavy volume, following an interim update on the extended Hybryte treatment study.
Via Benzinga · July 9, 2024

UniQure stock is up on Tuesday as QURE investors react to positive clinical trial data for its Huntington’s Disease treatment candidate.
Via InvestorPlace · July 9, 2024

Soligenix stock is up on Tuesday with heavy trading of SNGX shares alongside positive clinical trial data from the company.
Via InvestorPlace · July 9, 2024